Invention Grant
- Patent Title: Carbocyclic nucleoside reverse transcriptase inhibitors
-
Application No.: US16212121Application Date: 2018-12-06
-
Publication No.: US11040975B2Publication Date: 2021-06-22
- Inventor: Francois-Rene Alexandre , Rachid Rahali , Izzat Raheem , Christophe Parsy
- Applicant: Merck Sharp & Dohme Corp. , Idenix Pharmaceuticals LLC
- Applicant Address: US NJ Rahway; US MA Cambridge
- Assignee: Merck Sharp & Dohme Corp.,Idenix Pharmaceuticals LLC
- Current Assignee: Merck Sharp & Dohme Corp.,Idenix Pharmaceuticals LLC
- Current Assignee Address: US NJ Rahway; US MA Cambridge
- Agent Carol S. Quagliato; John C. Todaro
- Main IPC: C07D473/40
- IPC: C07D473/40 ; C07D473/32 ; C07D239/47 ; C07D239/54 ; A61K31/675 ; A61K31/7072 ; A61K31/522 ; A61K31/513 ; C07F9/6561 ; A61K31/52 ; C07F9/6512
Abstract:
The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.
Public/Granted literature
- US20190177326A1 CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Public/Granted day:2019-06-13
Information query
